학술논문
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials
Document Type
Article
Author
Source
In Atherosclerosis September 2019 288:194-202
Subject
Language
ISSN
0021-9150